| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2023 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43TR004525 | Engineering next generation probiotics for delivery of therapeutics | 000 | 1 | NIH | 12/12/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42AI122855 | A method for accurate and sensitive detection of HIV drug-resistant minority variants | 000 | 3 | NIH | 6/16/2025 | $0 |
| | 2025 | 2022 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 6 | NIH | 5/5/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $350,000 ) |
| | 2024 | 2024 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42GM151928 | Metabolism and Mitochondrial Energetics Therapy for Septic Shock | 000 | 1 | NIH | 9/12/2024 | $350,000 |
| | 2024 | 2024 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42GM151928 | Metabolism and Mitochondrial Energetics Therapy for Septic Shock | 001 | 1 | NIH | 9/24/2024 | $0 |
| | 2024 | 2022 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R44DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 3 | NIH | 6/10/2024 | $0 |
| | 2024 | 2022 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 6 | NIH | 8/5/2024 | $0 |
| | 2024 | 2021 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 3 | NIH | 3/14/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,325,000 ) |
| | 2023 | 2023 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43TR004525 | Engineering next generation probiotics for delivery of therapeutics | 001 | 1 | NIH | 8/15/2023 | $0 |
| | 2023 | 2023 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42AI122855 | A method for accurate and sensitive detection of HIV drug-resistant minority variants | 000 | 3 | NIH | 6/13/2023 | $1,000,000 |
| | 2023 | 2023 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43TR004525 | Engineering next generation probiotics for delivery of therapeutics | 000 | 1 | NIH | 7/27/2023 | $325,000 |
| | 2023 | 2021 | MEDOSOME BIOTEC LLC | 3416 S ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 3 | NIH | 5/25/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,791,829 ) |
| | 2022 | 2022 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R44DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 3 | NIH | 7/7/2022 | $776,646 |
| | 2022 | 2022 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42AI122855 | A method for accurate and sensitive detection of HIV drug-resistant minority variants | 000 | 2 | NIH | 7/19/2022 | $999,999 |
| | 2022 | 2022 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 6 | NIH | 7/7/2022 | $985,330 |
| | 2022 | 2021 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 3 | NIH | 3/21/2022 | $0 |
| | 2022 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41DK123953 | Development of a Novel Therapeutic for Hyperthyroidism | 000 | 1 | NIH | 2/16/2022 | $0 |
| | 2022 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43HL149554 | Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7 | 000 | 1 | NIH | 2/3/2022 | $0 |
| | 2022 | 2017 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 1 | NIH | 9/26/2022 | $15,206 |
| | 2022 | 2017 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41HD092133 | Development of CaSR nutrient therapy for childhood diarrhea | 000 | 1 | NIH | 9/26/2022 | $14,648 |
|
| Issue Date FY: 2021 ( Subtotal = $2,527,801 ) |
| | 2021 | 2021 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 3 | NIH | 5/20/2021 | $700,593 |
| | 2021 | 2021 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 001 | 5 | NIH | 8/18/2021 | $992,757 |
| | 2021 | 2021 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R44DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 2 | NIH | 7/19/2021 | $834,451 |
| | 2021 | 2018 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 3 | NIH | 6/14/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,993,274 ) |
| | 2020 | 2020 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 001 | 4 | NIH | 7/13/2020 | $1,000,000 |
| | 2020 | 2020 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 2 | NIH | 5/14/2020 | $993,274 |
| | 2020 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 001 | 1 | NIH | 9/5/2020 | $0 |
| | 2020 | 2018 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 3 | NIH | 7/13/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $624,804 ) |
| | 2019 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD097911 | Prevention of White Matter Injury in Premature Infants | 000 | 1 | NIH | 5/16/2019 | $223,899 |
| | 2019 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41DK123953 | Development of a Novel Therapeutic for Hyperthyroidism | 000 | 1 | NIH | 9/17/2019 | $225,000 |
| | 2019 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41DK123953 | Development of a Novel Therapeutic for Hyperthyroidism | 001 | 1 | NIH | 9/22/2019 | $0 |
| | 2019 | 2019 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43HL149554 | Optimization of recombinant probiotics for oral delivery of ACE2/Ang-(1-7 | 000 | 1 | NIH | 9/14/2019 | $225,000 |
| | 2019 | 2017 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 1 | NIH | 7/24/2019 | -$15,206 |
| | 2019 | 2017 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41HD092133 | Development of CaSR nutrient therapy for childhood diarrhea | 000 | 1 | NIH | 7/25/2019 | -$14,648 |
| | 2019 | 2016 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41AI122735 | Development of Optimized AAV Serotype Vectors for Human Gene Therapy | 000 | 1 | NIH | 1/14/2019 | -$19,241 |
|
| Issue Date FY: 2018 ( Subtotal = $695,065 ) |
| | 2018 | 2018 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R42HD089804 | Personalized dosing of dichloroacetate for the treatment of rare and common diseases | 000 | 3 | NIH | 9/10/2018 | $695,065 |
| | 2018 | 2018 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43DK112540 | Next generation quantitative HCV drug resistance assay | 001 | 1 | NIH | 3/27/2018 | -$50,000 |
| | 2018 | 2018 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R43DK112540 | Next generation quantitative HCV drug resistance assay | 000 | 1 | NIH | 2/23/2018 | $50,000 |
| | 2018 | 2016 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41AI122855 | A method for accurate and sensitive detection of HIV drug-resistant minority variants | 000 | 1 | NIH | 7/31/2018 | $0 |
| | 2018 | 2016 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41AR068158 | Novel therapies for inherited muscle diseases | 000 | 1 | NIH | 5/31/2018 | $0 |
| | 2018 | 2015 | MEDOSOME BIOTEC LLC | 3416 ASHWOOD DR | BLOOMINGTON | IN | 47401-9762 | MONROE | USA | R41NS095475 | Discovery of Oligodendrocyte Stimulators | 000 | 1 | NIH | 2/8/2018 | $0 |
|
|
